Forward Therapeutics Receives FDA IND Clearance for Phase 2 FT2109 Study
Forward Therapeutics says the FDA cleared its investigational new drug application to begin a Phase 2 study of FT2109 in psoriatic arthritis.
Forward Therapeutics says the FDA cleared its investigational new drug application to begin a Phase 2 study of FT2109 in psoriatic arthritis.